Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | CASP7 | P55210 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608447 | 0.88 | APP (0.43) | CDK2SYKKDRKMT2ACDK1 | |
| SCHEMBL3581478 | 0.88 | GRM5 (0.35) | KDRMEN1KMT2AMAPK1APP | |
| SCHEMBL3594445 | 0.88 | CDK5 (0.31) | CDK5CDK5R1 | |
| SCHEMBL4825740 | 0.68 | PKM (0.34) | — | |
| SCHEMBL4825230 | 0.68 | CES2 (0.39) | CYP1A2CYP3A4ALDH1A1CYP2C9TSHR | |
| SCHEMBL3583812 | 0.66 | SYK (0.61) | CCNA2CDK2CDK5CDK5R1USP2 | |
| SCHEMBL3592355 | 0.65 | SYK (0.52) | CCNA2CDK2CDK5CDK5R1USP2 | |
| SCHEMBL14603934 | 0.64 | TSHR (0.52) | ALDH1A1TSHREGFRMEN1KMT2A | |
| SCHEMBL4826527 | 0.64 | PDE4A (0.50) | NPC1RAB9A | |
| SCHEMBL22191547 | 0.64 | SYK (0.60) | CCNA2CDK2CDK5CDK5R1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | CCNA2 1092/4885CDK2 452/4885CDK5 269/4885 |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | CCNA2 1092/4885CDK2 452/4885CDK5 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.